1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
D000328:Adult; D000941:Antigens; D001706:Biopsy; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004100:Dihydroxycholecalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006934:Hypercalcemia / Q000139:chemically induced; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000473:pathology; D007085:Ilium / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000188:drug therapy / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood* / Q000276:immunology; D010758:Phosphorus / Q000097:blood
D000941:Antigens; D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010758:Phosphorus; D002118:Calcium